OSE Immuno

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

22 May 2025 22:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Strategic Collaboration to Pioneer Novel mRNA Technologies

21 May 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab

05 May 2025 09:30:00 By Nasdaq GlobeNewswire

Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025

29 Apr 2025 22:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Highlights Abstracts Selected for Presentation at ASCO 2025

23 Apr 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics to Present Groundbreaking Extension Period Data on Lusvertikimab at DDW 2025

08 Apr 2025 22:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025

03 Apr 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

26 Mar 2025 10:20:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics and GERCOR Announce Positive Topline Phase 2 Result for Clinical Trial TEDOPaM Evaluating OSE2101 (Tedopi®) in Advanced Pancreatic Cancer

11 Mar 2025 10:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD

06 Mar 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

23 Feb 2025 22:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20th Congress of ECCO

20 Feb 2025 09:05:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics and Scienta Lab Establish Strategic Partnership to Leverage Artificial Intelligence in Precision Immunotherapy

29 Jan 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20th Congress of ECCO

27 Jan 2025 22:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer

13 Jan 2025 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Positive Clinical Progress for Late-Stage Proprietary Cancer Vaccine Tedopi®

11 Dec 2024 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Strengthens Leadership and Executive Committee

02 Dec 2024 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis

03 Nov 2024 22:30:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index

17 Oct 2024 09:00:00 By Nasdaq GlobeNewswire

OSE Immunotherapeutics Announces Historic H1 2024 Results and Provides Corporate Update

26 Sep 2024 09:00:00 By Nasdaq GlobeNewswire